-
Combined hepatocellular-cholangiocarcinoma: biology, diagnosis, and management Liver Cancer (IF 13.8) Pub Date : 2023-04-24 Liangtao Ye, Julia S. Schneider, Najib Ben Khaled, Peter Schirmacher, Carolin Seifert, Lea Frey, Yulong He, Andreas Geier, Enrico N. De Toni, Changhua Zhang, Florian P. Reiter
Background Combined hepatocellular-cholangiocarcinoma (cHCC-iCCA) is a rare type of primary liver cancer displaying characteristics of both hepatocytic and cholangiocytic differentiation. Summary Because of its aggressive nature, patients with cHCC-iCCA exhibit a poorer prognosis than those with HCC. Surgical resection and liver transplantation may be considered as curative treatment approaches; however
-
-
HBV DNA Integration into Telomerase or MLL4 Genes and TERT Promoter Point Mutation as Three Independent Signatures in Subgrouping HBV-related HCC with distinct features Liver Cancer (IF 13.8) Pub Date : 2023-04-17 Chiao-Ling Li, Chia-Lang Hsu, You-Yu Lin, Ming-Chih Ho, Rey-Heng Hu, Chi-Ling Chen, Tung-Ching Ho, Yung-Feng Lin, Shih-Feng Tsai, Sheng-Tai Tzeng, Chin-Fang Huang, Ya-Chun Wang, Shiou-Hwei Yeh, Pei-Jer Chen
Introduction: A set of genetic mutations to classify hepatocellular carcinoma (HCC) useful to clinical studies is an unmet need. Hepatitis B virus-related HCC (HBV-HCC) harbors a unique genetic mutation, namely the HBV integration, among other somatic endogenous gene mutations. We explored a combination of HBV DNA integrations and common somatic mutations to classify HBV-HCC by using a capture-sequencing
-
Real-time fluorescence imaging to identify cholangiocarcinoma in the extrahepatic biliary tree using an enzyme-activatable probe Liver Cancer (IF 13.8) Pub Date : 2023-04-14 Ryugen Takahashi, Takeaki Ishizawa, Yoshinori Inagaki, Mariko Tanaka, Akira Ogasawara, Yugo Kuriki, Kyohhei Fujita, Mako Kamiya, Tetsuo Ushiku, Yasuteru Urano, Kiyoshi Hasegawa
Introduction Complete resection is the only possible treatment for cholangiocarcinoma in the extrahepatic biliary tree (eCCA), although current imaging modalities are limited in their ability to accurately diagnose longitudinal spread. We aimed to develop fluorescence imaging techniques for real-time identification of eCCA using an enzyme-activatable probe, which emits fluorescence immediately after
-
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition) Liver Cancer (IF 13.8) Pub Date : 2023-04-05 Jian Zhou, Huichuan Sun, Zheng Wang, Wenming Cong, Mengsu Zeng, Weiping Zhou, Ping Bie, Lianxin Liu, Tianfu Wen, Ming Kuang, Guohong Han, ZhiPing Yan, Maoqiang Wang, Ruibao Liu, Ligong Lu, Zhenggang Ren, ZhaoChong Zeng, Ping Liang, Changhong Liang, Min Chen, Fuhua Yan, Wenping Wang, Jinlin Hou, Yuan Ji, Jingping Yun, Xueli Bai, Dingfang Cai, Weixia Chen, Yongjun Chen, Wenwu Cheng, Shuqun Cheng, Chaoliu
Background: Primary liver cancer, around 75%–85% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people. Summary: Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China in June 2017, which were updated by
-
TACE for treatment-naive HCC has different treatment effects depending on central or peripheral tumor-location Liver Cancer (IF 13.8) Pub Date : 2023-03-31 Kazuo Asano, Ken Kageyama, Akira Yamamoto, Atsushi Jogo, Sawako Uchida-Kobayashi, Etsuji Sohgawa, Kazuki Murai, Norifumi Kawada, Yukio Miki
Introduction: The purpose of this study was to evaluate the treatment efficacy of transcatheter arterial chemo-embolization (TACE) for treatment-naive hepatocellular carcinoma (HCC) according to tumor location and burden. Methods: Between 2010 and 2019, consecutive patients who underwent TACE as the first treatment were enrolled. Tumors were classified into two categories based on their location, as
-
Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-analysis of Randomized Trials Liver Cancer (IF 13.8) Pub Date : 2023-03-28 Darren Jun Hao Tan, Ansel Shao Pin Tang, Wen Hui Lim, Cheng Han Ng, Benjamin Nah, Clarissa Fu, Jieling Xiao, Benjamin Koh, Phoebe Wen Lin Tay, Eunice X Tan, Margaret Teng, Nicholas Syn, Mark D Muthiah, Nobuharu Tamaki, Sung Won Lee, Beom Kyung Kim, Thomas Yau, Arndt Vogel, Rohit Loomba, Daniel Q. Huang
Background: Emerging data suggest that outcomes for advanced hepatocellular carcinoma (HCC) treated with sorafenib may have improved over time. We aimed to provide robust, time-to-event estimates of survival outcomes for sorafenib in advanced HCC. Summary: In this systematic review and individual patient data meta-analysis of randomized-controlled trials (RCTs), we searched MEDLINE and Embase from
-
Genomic and Immune Features in an Intrahepatic Cholangiocarcinoma Patient with Microsatellite Instability-High Suffered Rapid Acquired Resistance to PD-1 Inhibitor Liver Cancer (IF 13.8) Pub Date : 2023-03-28 Zhuo Cheng, Tianmei Zeng, Guang Yang, Di Liu, Zhi Zheng, Zhengang Yuan
Introduction: Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive liver malignancy with poor prognosis. Recently, the development of immune checkpoint inhibitors (ICIs), such as programmed cell death 1 (PD-1) inhibitors, has emerged as a promising strategy in multiple tumor types, including ICC. Microsatellite instability-high (MSI-H) is an important biomarker for ICIs in solid tumors. The
-
Reply to “Surgical resection or radiofrequency ablation for small hepatocellular carcinoma” Liver Cancer (IF 13.8) Pub Date : 2023-03-23 Yoshikuni Kawaguchi, Ryosuke Tateishi, Norihiro Kokudo, Kiyoshi Hasegawa
Not applicable
-
Definitive liver radiotherapy for intrahepatic cholangiocarcinoma with extrahepatic metastases Liver Cancer (IF 13.8) Pub Date : 2023-03-16 Brian De, Rituraj Upadhyay, Kaiping Liao, Tiffany Kumala, Christopher Shi, Grace Dodoo, Joseph Abi Jaoude, Kelsey L. Corrigan, Gohar S. Manzar, Kathryn E. Marqueen, Vincent Bernard, Sunyoung S Lee, Kanwal P.S. Raghav, Jean-Nicolas Vauthey, Ching-Wei Tzeng, Hop S. Tran Cao, Grace Lee, Jennifer Wo, Theodore S Hong, Christopher H Crane, Bruce D. Minsky, Grace L. Smith, Emma B. Holliday, Cullen M. Taniguchi
Introduction: Tumor-related liver failure (TRLF) is the most common cause of death in patients with intrahepatic cholangiocarcinoma (ICC). Though we previously showed that liver radiotherapy (L-RT) for locally advanced ICC is associated with less frequent TRLF and longer overall survival (OS), the role of L-RT for patients with extrahepatic metastatic disease (M1) remains undefined. We sought to compare
-
Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update Liver Cancer (IF 13.8) Pub Date : 2023-03-09
NA
-
Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update Liver Cancer (IF 13.8) Pub Date : 2023-03-09 Masatoshi Kudo
NA
-
Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study Liver Cancer (IF 13.8) Pub Date : 2023-03-04 Masatoshi Kudo, Richard S. Finn, Ann-Lii Cheng, Andrew X. Zhu, Michel Ducreux, Peter R. Galle, Naoya Sakamoto, Naoya Kato, Michitaka Nakano, Jing Jia, Arndt Vogel
Introduction: Atezolizumab + bevacizumab showed survival benefit in patients with unresectable hepatocellular carcinoma (HCC) vs sorafenib in the Phase III IMbrave150 study. This exploratory analysis examined the prognostic impact of baseline albumin-bilirubin (ALBI) score. Methods: Patients with treatment-naïve unresectable HCC, ≥1 measurable untreated lesion and Child-Pugh Class A liver function
-
Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study Liver Cancer (IF 13.8) Pub Date : 2023-03-04
Introduction: Atezolizumab + bevacizumab showed survival benefit in patients with unresectable hepatocellular carcinoma (HCC) vs sorafenib in the Phase III IMbrave150 study. This exploratory analysis examined the prognostic impact of baseline albumin-bilirubin (ALBI) score. Methods: Patients with treatment-naïve unresectable HCC, ≥1 measurable untreated lesion and Child-Pugh Class A liver function
-
Computed Tomography–Defined Sarcopenia in Outcomes of Patients with Unresectable Hepatocellular Carcinoma Undergoing Radioembolisation: Assessment with Total Abdominal, Psoas, and Paraspinal Muscles Liver Cancer (IF 13.8) Pub Date : 2023-02-23 Chih-Horng Wu, Ming-Chih Ho, Chien-Hung Chen, Ja-Der Liang, Kai-Wen Huang, Mei-Fang Cheng, Chih-Kai Chang, Chia-Hung Chang, Po-Chin Liang
Introduction: Sarcopenia is an adverse prognostic factor in patients with liver cirrhosis and hepatocellular carcinoma (HCC). Image-based sarcopenia assessment allows a standardized method to assess abdominal skeletal muscle. However, which is an index muscle for sarcopenia remains unclear. Therefore, we investigated whether sarcopenia defined according to different muscle groups with computed tomography
-
Computed Tomography–Defined Sarcopenia in Outcomes of Patients with Unresectable Hepatocellular Carcinoma Undergoing Radioembolisation: Assessment with Total Abdominal, Psoas, and Paraspinal Muscles Liver Cancer (IF 13.8) Pub Date : 2023-02-23
Introduction: Sarcopenia is an adverse prognostic factor in patients with liver cirrhosis and hepatocellular carcinoma (HCC). Image-based sarcopenia assessment allows a standardized method to assess abdominal skeletal muscle. However, which is an index muscle for sarcopenia remains unclear. Therefore, we investigated whether sarcopenia defined according to different muscle groups with computed tomography
-
-
-
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial Liver Cancer (IF 13.8) Pub Date : 2023-02-14 Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn
Introduction: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival (OS) or progression-free survival (PFS) superiority were not met at the final analysis. Outcomes based on an additional 18 months of follow-up are reported
-
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial Liver Cancer (IF 13.8) Pub Date : 2023-02-14
Introduction: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival (OS) or progression-free survival (PFS) superiority were not met at the final analysis. Outcomes based on an additional 18 months of follow-up are reported
-
Impact of Intrahepatic External Beam Radiotherapy in Advanced Hepatocellular Carcinoma Patients Treated with Tyrosine Kinase Inhibitors Liver Cancer (IF 13.8) Pub Date : 2023-02-10 Myung Ji Goh, Hee Chul Park, Jeong Il Yu, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Dong Hyun Sinn, Moon Seok Choi
Introduction: We aimed to investigate whether concurrent use of intrahepatic external beam radiotherapy (EBRT) is a viable option for patients with advanced hepatocellular carcinoma (HCC) undergoing tyrosine kinase inhibitor (TKI) therapy. Methods: A total of 453 patients with Barcelona Clinic Liver Cancer-stage C (BCLC-C) HCC, who started first-line treatment with TKI with intrahepatic EBRT (TKI +
-
Impact of Intrahepatic External Beam Radiotherapy in Advanced Hepatocellular Carcinoma Patients Treated with Tyrosine Kinase Inhibitors Liver Cancer (IF 13.8) Pub Date : 2023-02-10
Introduction: We aimed to investigate whether concurrent use of intrahepatic external beam radiotherapy (EBRT) is a viable option for patients with advanced hepatocellular carcinoma (HCC) undergoing tyrosine kinase inhibitor (TKI) therapy. Methods: A total of 453 patients with Barcelona Clinic Liver Cancer-stage C (BCLC-C) HCC, who started first-line treatment with TKI with intrahepatic EBRT (TKI +
-
Association Between Smoking Cessation and the Risk of Cholangiocarcinoma and Ampulla of Vater Cancer: A Nationwide Cohort Study Liver Cancer (IF 13.8) Pub Date : 2023-02-09
Introduction: The association between smoking cessation and intrahepatic and extrahepatic cholangiocarcinoma (iCCA and eCCA) risk is unclear. Furthermore, the association in individuals with preexisting risk factors is unknown. We aimed to investigate the association between smoking status (especially smoking cessation) and CCA risk according to individuals’ glycemic status. Methods: In this nationwide
-
Association Between Smoking Cessation and the Risk of Cholangiocarcinoma and Ampulla of Vater Cancer: A Nationwide Cohort Study Liver Cancer (IF 13.8) Pub Date : 2023-02-09
Introduction: The association between smoking cessation and intrahepatic and extrahepatic cholangiocarcinoma (iCCA and eCCA) risk is unclear. Furthermore, the association in individuals with preexisting risk factors is unknown. We aimed to investigate the association between smoking status (especially smoking cessation) and CCA risk according to individuals’ glycemic status. Methods: In this nationwide
-
Achievement of Complete Response and Drug-free Status by Atezolizumab Plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-stage Hepatocellular Carcinoma: A Multicenter Proof-of-Concept Study Liver Cancer (IF 13.8) Pub Date : 2023-02-07 Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, Kaoru Tsuchiya, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Naoshi Nishida, Chikara Ogawa, Tetsu Tomonari, Noriaki Nakamura, Hidekatsu Kuroda, Atsushi Takebe, Yoshifumi Takeyama, Masaaki Hidaka, Susumu Eguchi, Stephen L Chan, Masayuki Kurosaki, Namiki Izumi
Introduction: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as reported in the IMbrave150 trial. When tumor shrinkage is obtained, achieving complete response (CR) is possible in many cases using curative conversion with resection, ablation, or super selective transarterial chemoembolization
-
Achievement of Complete Response and Drug-free Status by Atezolizumab Plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-stage Hepatocellular Carcinoma: A Multicenter Proof-of-Concept Study Liver Cancer (IF 13.8) Pub Date : 2023-02-07
Introduction: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as reported in the IMbrave150 trial. When tumor shrinkage is obtained, achieving complete response (CR) is possible in many cases using curative conversion with resection, ablation, or super selective transarterial chemoembolization
-
Contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) in hepatocellular carcinoma ≤ 5cm: biological characteristics and patient outcomes Liver Cancer (IF 13.8) Pub Date : 2023-01-24 Wen-jia Cai, Minghua Ying, Rong-qin Zheng, Jintang Liao, Baoming Luo, Lina Tang, Wen Cheng, Hong Yang, An Wei, Yilin Yang, Hui Wang, Yan-chun Luo, Cun Liu, Hui Zhong, Qi Yang, Jie Yu, Ping Liang
Introduction: The present study aimed to evaluate the influence of biological characteristics of hepatocellular carcinoma (HCC) on the Liver Imaging Reporting and Data System (LI-RADS) v2017 category of contrast-enhanced ultrasound (CEUS) in patients with high risk and compare the outcomes among different categories after radical resection. Methods: Between June 2017 and December 2020, standardized
-
Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Hepatocellular Carcinoma ≤5 cm: Biological Characteristics and Patient Outcomes Liver Cancer (IF 13.8) Pub Date : 2023-01-24
Introduction: The present study aimed to evaluate the influence of biological characteristics of hepatocellular carcinoma (HCC) on the Liver Imaging Reporting and Data System (LI-RADS) v2017 category of contrast-enhanced ultrasound (CEUS) in patients with high risk and compare the outcomes among different categories after radical resection. Methods: Between June 2017 and December 2020, standardized
-
Optimizing survival benefit by surgical resection by the seven-eleven criteria in Barcelona clinic liver cancer stage A/B hepatocellular carcinoma beyond the Milan criteria Liver Cancer (IF 13.8) Pub Date : 2023-01-19
Introduction: Optimal treatment of hepatocellular carcinoma (HCC) beyond the Milan criteria is in debate. We aimed to identify candidates for surgical resection (SR) in Barcelona Clinic Liver Cancer (BCLC) –A/B HCC beyond the Milan criteria with survival benefit. Methods: Patients with BCLC-A/B HCC beyond the Milan criteria at the National Taiwan University Hospital during 2005 and 2019 were screened
-
Optimizing survival benefit by surgical resection by the seven-eleven criteria in Barcelona clinic liver cancer stage A/B hepatocellular carcinoma beyond the Milan criteria Liver Cancer (IF 13.8) Pub Date : 2023-01-19
Introduction: Optimal treatment of hepatocellular carcinoma (HCC) beyond the Milan criteria is in debate. We aimed to identify candidates for surgical resection (SR) in Barcelona Clinic Liver Cancer (BCLC) –A/B HCC beyond the Milan criteria with survival benefit. Methods: Patients with BCLC-A/B HCC beyond the Milan criteria at the National Taiwan University Hospital during 2005 and 2019 were screened
-
Efficacy of Local Treatment in Lymph Node Metastasis from Hepatocellular Carcinoma Liver Cancer (IF 13.8) Pub Date : 2023-01-18 Byung min Lee, Jin-Young Choi, Jinsil Seong
Introduction: We aimed to investigate the significance of lymph node metastasis from hepatocellular carcinoma and the efficacy of local treatment. Methods : We included patients diagnosed with hepatocellular carcinoma with lymph node metastasis. The pattern of lymph node metastasis was evaluated based on imaging examinations and stratified by three locations: regional (group A), beyond regional intra-abdomen
-
Predictive and prognostic potential of liver function assessment in patients with advanced hepatocellular carcinoma: a systematic literature review Liver Cancer (IF 13.8) Pub Date : 2023-01-17 Arndt Vogel, Robin Kate Kelley, Philip Johnson, Philippe Merle, Thomas Yau, Masatoshi Kudo, Tim Meyer, Lorenza Rimassa
Introduction We conducted a systematic literature review to assess the utility of liver function assessments for predicting disease prognosis and response to systemic anticancer therapy in patients with advanced hepatocellular carcinoma (aHCC). Methods This was a PRISMA-standard review and was registered with PROSPERO (CRD42021244588). MEDLINE and Embase were systematically searched (March 24, 2021)
-
Long-term regression after discontinuation of regorafenib administered for sorafenib-refractory hepatocellular carcinoma Liver Cancer (IF 13.8) Pub Date : 2023-01-16
A patient with hepatocellular carcinoma(HCC) staged Barcelona Clinic for Liver Cancer stage B started chemotherapy because of intrahepatic recurrence after hepatic segmentectomy. Regorafenib was started as a second-line treatment due to refractory to sorafenib treatment, but was discontinued after 26 months due to side effects. After two years of follow-up, the patients achieved unexpected long-term
-
The 12th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2022) Liver Cancer (IF 13.8) Pub Date : 2023-01-12
na Liver Cancer 2022;11(suppl 1):1–56
-
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity Liver Cancer (IF 13.8) Pub Date : 2023-01-06 Masatoshi Kudo
NA
-
Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-analysis Liver Cancer (IF 13.8) Pub Date : 2022-12-29 Yizhou Zhang, Minghao Wang, Qichen Chen, Yiqiao Deng, Jinghua Chen, Yimin Dai, Sheng Luo, Jianming Xu, Hong Zhao, Jianqiang Cai
Introduction: To investigate the incidence and spectrum of adverse events in unresectable hepatocellular carcinoma (HCC) patients treated with immune checkpoint inhibitors (ICIs) or ICI-based combinations. Methods: The study protocol was prospectively registered on PROSPERO (CRD42022319255). We searched PubMed, EMBASE, and the Cochrane Library for published clinical trials from database inception to
-
Antibiotics associated with lower survival in hepatocellular cancer patients receiving immune checkpoint inhibitors independent of tumor status Liver Cancer (IF 13.8) Pub Date : 2022-12-29 Ka Shing Cheung, Lok Ka Lam, Wai K. Leung
not applicable
-
Elderly Patients with Hepatocellular Carcinoma benefit from Liver Transplantation as much as younger ones Liver Cancer (IF 13.8) Pub Date : 2022-12-26 Jens Mittler, Stefan Heinrich, Martina Koch, Maria Hoppe-Lotichius, Ali Hadian, Arndt Weinmann, Roman Kloeckner, Peter Robert. Galle, Hauke Lang
Abstract: Introduction: The literature on liver transplantation (LT) for cirrhosis-associated hepatocellular carcinoma (cirr-HCC) in elderly patients (≥65 years of age) is scarce. The aim of this study was therefore to analyze the outcome after LT for cirr-HCC in elderly patients in our single-center experience. Methods: All consecutive patients who underwent LT for cirr-HCC at our center were identified
-
Surgical resection or radiofrequency ablation for small hepatocellular carcinoma Liver Cancer (IF 13.8) Pub Date : 2022-12-23
not required
-
Relationship of atezolizumab plus bevacizumab treatment with muscle volume loss in unresectable hepatocellular carcinoma patients– multicenter analysis Liver Cancer (IF 13.8) Pub Date : 2022-12-08 Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Naganuma, Masaki Kaibori, Takaaki
Background/Aim: There is no known report regarding the relationship of atezolizumab plus bevacizumab (Atez/Bev) treatment with muscle volume loss (MVL) in unresectable hepatocellular carcinoma (u-HCC) patients. This study aimed to elucidate the clinical relationship between MVL and Atez/Bev. Materials/Methods: From September 2020 to December 2021, 229 u-HCC patients treated with Atez/Bev and with muscle
-
Imaging Diagnosis of various HCC subtypes and Its Hypervascular Mimics: Differential Diagnosis Based on Conventional Interpretation and Artificial Intelligence Liver Cancer (IF 13.8) Pub Date : 2022-12-06 Yasunori Minami, Naoshi Nishida, Masatoshi Kudo
Background. Hepatocellular carcinoma (HCC) is unique among malignancies, and its characteristics on contrast imaging modalities allow for a highly accurate diagnosis. The radiological differentiation of focal liver lesions is playing an increasingly important role, and the Liver Imaging Reporting and Data System (LI-RADS) adopts a combination of major features including arterial phase hyperenhancement
-
Proton beam therapy versus radiofrequency ablation for patients with treatment-naïve single hepatocellular carcinoma: a propensity score analysis Liver Cancer (IF 13.8) Pub Date : 2022-12-06 Yuta Sekino, Ryosuke Tateishi, Nobuyoshi Fukumitsu, Toshiyuki Okumura, Kazushi Maruo, Takashi Iizumi, Haruko Numajiri, Masashi Mizumoto, Tatsuya Minami, Ryo Nakagomi, Masaya Sato, Yoshinari Asaoka, Hayato Nakagawa, Yuki Hayata, Naoto Fujiwara, Shuichiro Shiina, Kazuhiko Koike, Hideyuki Sakurai
Introduction: Proton beam therapy (PBT) is known to be an effective locoregional treatment for hepatocellular carcinoma (HCC). However, few comparative studies in treatment-naïve cases have been reported. The aim of this study was to compare the survival outcomes of PBT with those of radiofrequency ablation (RFA) in patients with treatment-naïve solitary HCC. Methods: Ninety-five consecutive patients
-
Trends and Disparities in Stage-specific Incidence of Hepatocellular Carcinoma among US Adults, 2004-2019 Liver Cancer (IF 13.8) Pub Date : 2022-12-05 Haoting Shi, Jingxuan Huang, Shi Zhao, Yiwen Jin, Rong Cai, Jinjun Ran
Introduction: To determine the stage-specific incidence trend of hepatocellular carcinoma (HCC) among US adults. Methods: The age-adjusted incidence rate was extracted from Surveillance, Epidemiology, and End Results database for localized, regional and distant HCC. Trend analyses were conducted in the overall population and stratified by demographic and sociodemographic variables. The annual percentage
-
-
Acknowledgement to Reviewers Liver Cancer (IF 13.8) Pub Date : 2022-12-02
Liver Cancer 2022;11:583–584
-
-
Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study Liver Cancer (IF 13.8) Pub Date : 2022-11-30 Jia-Yi Wu, Zhi-Bo Zhang, Jian-Yin Zhou, Jing-Peng Ke, Yan-Nan Bai, Yu-Feng Chen, Jun-Yi Wu, Song-Qiang Zhou, Shuang-Jia Wang, Zhen-Xin Zeng, Yi-Nan Li, Fu-Nan Qiu, Bin Li, Mao-Lin Yan
Introduction. The actual rate of conversion surgery and its prognostic advantages remain unclear. This study aimed to assess the outcomes of salvage surgery after conversion therapy with triple therapy (transcatheter arterial chemoembolization (TACE) combined with lenvatinib plus anti-PD-1 antibodies) in patients with initially unresectable hepatocellular carcinoma (uHCC). Methods. Patients with initially
-
Risk factors for Early onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma. Liver Cancer (IF 13.8) Pub Date : 2022-11-29 Yuwa Ando, Tomokazu Kawaoka, Masanari Kosaka, Yuki Shirane, Yusuke Johira, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yumi Kosaka, Shinsuke Uchikawa, Kenichiro Kodama, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Masami Yamauchi, Wataru Okamoto, Shoichi Takahashi, Michio Imamura, Hiroshi Aikata
Introduction Proteinuria is one of the adverse events of atezolizumab plus bevacizumab combination therapy (Atezo+Bev) and can cause interruption in the use of Bev. However, the risk factors for proteinuria in patients with hepatocellular carcinoma (HCC) who are receiving Atezo+Bev have not yet been investigated. The aim of this study was to identify the risk factors for early onset of proteinuria
-
Tumor radiomic features on pretreatment MRI to predict response to lenvatinib plus an anti–PD-1 antibody in advanced hepatocellular carcinoma: a multicenter study Liver Cancer (IF 13.8) Pub Date : 2022-11-28 Bin Xu, Sanyuan Dong, Xue-Li Bai, Tian-Qiang Song, Bo-Heng Zhang, Le-Du Zhou, Yong-Jun Chen, Zhi-Ming Zeng, Kui Wang, Hai-Tao Zhao, Na Lu, Wei Zhang, Xu-Bin Li, Su-Su Zheng, Guo Long, Yu-Chen Yang, Hua-Sheng Huang, Lan-Qing Huang, Yun-Chao Wang, Fei Liang, Xiao-Dong Zhu, Cheng Huang, Ying-Hao Shen, Jian Zhou, Meng-Su Zeng, Jia Fan, Sheng-Xiang Rao, Hui-Chuan Sun
Introduction: Lenvatinib plus an anti–PD-1 antibody has shown promising anti-tumor effects in patients with advanced hepatocellular carcinoma (HCC), but with clinical benefit limited to a subset of patients. We developed and validated a radiomic-based model to predict objective response to this combination therapy in advanced HCC patients. Methods: Patients (N = 170) who received first-line combination
-
IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma—An Exploratory Analysis of the Phase III Study Liver Cancer (IF 13.8) Pub Date : 2022-11-28
Introduction: The Phase III IMbrave150 study established atezolizumab + bevacizumab as standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis reports efficacy and safety results in patients with baseline Barcelona Clinic Liver Cancer (BCLC) Stage B disease. Methods: Patients with systemic treatment-naive unresectable HCC and Child-Pugh Class A liver
-
Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment Liver Cancer (IF 13.8) Pub Date : 2022-10-31 Shunichi Hosoda, Goki Suda, Takuya Sho, Koji Ogawa, Megumi Kimura, Zijian Yang, Sonoe Yoshida, Akinori Kubo, Yoshimasa Tokuchi, Takashi Kitagataya, Osamu Maehara, Shunsuke Ohnishi, Akihisa Nakamura, Ren Yamada, Masatsugu Ohara, Naoki Kawagishi, Mitsuteru Natsuizaka, Masato Nakai, Kenichi Morikawa, Ken Furuya, Masaru Baba, Yoshiya Yamamoto, Kazuharu Suzuki, Takaaki Izumi, Takashi Meguro, Katsumi Terashita
Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial. Methods: Patients with unresectable HCC treated with
-
Atezolizumab and bevacizumab combination therapy and sequential conversion hepatectomy for advanced fibrolamellar hepatocellular carcinoma presenting pseudoprogression Liver Cancer (IF 13.8) Pub Date : 2022-10-25 Ryota Matsuki, Naohiro Okano, Nobuhiro Hasui, Shohei Kawaguchi, Hirokazu Momose, Keiichiro Kitahama, Kiyotaka Nagahama, Masaharu Kogure, Yutaka Suzuki, Fumio Nagashima, Junji Shibahara, Hideaki Mori, Yoshihiro Sakamoto
Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare a rare subtype of hepatocellular carcinoma. The IMbrave150 trial demonstrated that atezolizumab and bevacizumab therapy (ABT) has better treatment outcomes than sorafenib for advanced HCC. However, since patients with known FLHCC were excluded from this trial, the effects of ABT on FLHCC remain unknown. We report the first case of ABT for advanced
-
Was Concurrent Antibiotic Use During Immunotherapy Associated with Higher Mortality for Patients with Advanced Hepatocellular Carcinoma? Liver Cancer (IF 13.8) Pub Date : 2022-10-10 Jia-Yu Hu, Si-Yu Liu, Chen Yuan, Ying Wang, Xiang-Min Tong
-
PD-1/CTLA-4 blockade leads to expansion of CD8+PD-1int TILs and results in tumor remission in experimental liver cancer Liver Cancer (IF 13.8) Pub Date : 2022-10-07 Sandra Bufe, Artur Zimmermann, Sarina Ravens, Immo Prinz, Laura Elisa Buitrago-Molina, Robert Geffers, Norman Woller, Florian Kühnel, Steven R. Talbot, Fatih Noyan, Michael Peter Manns, Heiner Wedemeyer, Matthias Hardtke-Wolenski, Elmar Jaeckel, Ana C. Davalos-Misslitz
Background: Checkpoint inhibitors act on exhausted CD8+ T cells and restore their effector function in chronic infections and cancer. The underlying mechanisms of action appear to differ between different types of cancer and are not yet fully understood. Methods: Here, we established a new orthotopic HCC model to study the effects of checkpoint blockade on exhausted CD8+ tumor-infiltrating lymphocytes
-
Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety Liver Cancer (IF 13.8) Pub Date : 2022-10-07 Philippe Merle, Masatoshi Kudo, Stanimira Krotneva, Kirhan Ozgurdal, Yun Su, Irina Proskorovsky
Introduction: The tyrosine kinase inhibitors regorafenib and cabozantinib remain the mainstay in second-line treatment of advanced hepatocellular carcinoma (HCC). There is currently no clear evidence of superiority in efficacy or safety to guide choice between the two treatments. Methods: We conducted an anchored matching-adjusted indirect comparison using individual patient data from the RESORCE trial
-
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and TACE to Achieve Synergistic Effects Liver Cancer (IF 13.8) Pub Date : 2022-10-06 Masatoshi Kudo
NA
-
Surgical outcomes of laparoscopic versus open hepatectomy for left hepatocellular carcinoma: Propensity score analyses using retrospective Japanese and Korean individual patient data Liver Cancer (IF 13.8) Pub Date : 2022-10-05 Masaki Kaibori, Kengo Yoshii, Yuzo Umeda, Takahito Yagi, Takehiro Okabayashi, Kenta Sui, Akira Mori, Yuhei Hamaguchi, Kiyoshi Kajiyama, Daisuke Hokuto, Kazuteru Monden, Tomoharu Yoshizumi, Yoriko Nomura, Kan Toriguchi, Jong Man Kim, Gi Hong Choi, Je Ho Ryu, Yangseok Koh, Koo Jeong Kang, Young Kyoung You, Kwang-Sik Chun, Young Seok Han, Chan Woo Cho, Young Il Choi, Dong-Sik Kim, Jae Do Yang, Keita Mori
Introduction: This study aimed to compare the prognostic impact of laparoscopic left hepatectomy (LLH) with that of open left hepatectomy (OLH) on patient survival after resection of left hepatocellular carcinoma (HCC). Methods: Among the 953 patients who received initial treatment for primary HCC that was resectable by either LLH or OLH from 2013 to 2017 in Japan and Korea, 146 patients underwent
-
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial Liver Cancer (IF 13.8) Pub Date : 2022-10-04 Zhenggang Ren, Michel Ducreux, Ghassan K. Abou-Alfa, Philippe Merle, Weijia Fang, Julien Edeline, Zhiwei Li, Lihua Wu, Eric Assenat, Sheng Hu, Lorenza Rimassa, Tao Zhang, Jean-Frédéric Blanc, Hongming Pan, Paul Ross, Chia-Jui Yen, Albert Tran, Guoliang Shao, Mohamed Bouattour, Yajin Chen, Tim Meyer, Jinlin Hou, David Tougeron, Yuxian Bai, Ming-Mo Hou, Zhiqiang Meng, John Wu, Vincent Li, Sandra Chica-Duque
Introduction: Tislelizumab (anti-programmed cell death protein 1 antibody) showed preliminary antitumor activity and tolerability in patients with advanced solid tumors, including hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of tislelizumab in patients with previously treated advanced HCC. Methods: The multi-regional phase 2 study, RATIONALE-208, examined single-agent
-
Erratum Liver Cancer (IF 13.8) Pub Date : 2022-10-04 Masatoshi Kudo, Masatoshi Kudo, Norihiro Kokudo, Jeong Min Lee, Riccardo Lencioni, Jens Ricke, Lewis R. Roberts, Augusto Villanueva, Ann-Lii Cheng, Michiie Sakamoto, Andrew X. Zhu, Namiki Izumi, Kwang-Hyub Han, Pei-Jer Chen, Jia Fan, Shenglong Ye, Massimo A. Iavarone, Jacques Belghiti, Jean Nicolas Vauthey, See Ching Chan, Pierce Chow, Irene Oi-lin Ng, Guido Torzilli, Richard S. Finn, Yasuharu Imai
Liver Cancer
-
Dietary fat composition affects hepatic angiogenesis and lymphangiogenesis in HCV core gene transgenic mice Liver Cancer (IF 13.8) Pub Date : 2022-09-16 Pan Diao, Yaping Wang, Fangping Jia, Xiaojing Wang, Xiao Hu, Takefumi Kimura, Yoshiko Sato, Kyoji Moriya, Kazuhiko Koike, Jun Nakayama, Naoki Tanaka
Introduction: Previous research has demonstrated that an isocaloric diet rich in trans fatty acid (TFA), saturated fatty acid (SFA), and cholesterol (Chol) promoted steatosis-derived hepatic tumorigenesis in hepatitis C virus core gene transgenic (HCVcpTg) mice in different manners. Growth factor signaling and ensuing angiogenesis/lymphangiogenesis are key factors in hepatic tumorigenesis that have